[1]陆阳,汤蕊嘉,谢璇丞,等.TACE联合阿帕替尼治疗中晚期肝细胞癌无进展生存时间的影响因素分析 [J].介入放射学杂志,2020,29(03):246-250.
　LU Yang,TANG Ruijia,XIE Xuancheng,et al.Analysis of influencing factors of progression-free survival in patients with advanced HCC treated with TACE combined with apatinib[J].journal interventional radiology,2020,29(03):246-250.
点击复制

TACE联合阿帕替尼治疗中晚期肝细胞癌无进展生存时间的影响因素分析

()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
29
期数:
2020年03
页码:
246-250
栏目:
肿瘤介入
出版日期:
2020-04-20

文章信息/Info

Title:
Analysis of influencing factors of progression-free survival in patients with advanced HCC treated with TACE combined with apatinib
作者:
陆阳; 汤蕊嘉; 谢璇丞; 赵卫
Author(s):
LU Yang;  TANG Ruijia;  XIE Xuancheng;  ZHAO Wei.
Department of Medical Imaging, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province 650032, China
关键词:
【关键词】　肝细胞癌; 肝动脉化疗栓塞; 阿帕替尼; 无进展生存时间; 影响因素
文献标志码:
A
摘要:
【摘要】　目的?探讨可能影响肝动脉化疗栓塞（TACE）联合阿帕替尼治疗中晚期肝细胞癌（HCC）患者无进展生存时间（PFS）的因素。方法?回顾性分析2016年1至3月收治的32例用TACE联合阿帕替尼治疗的中晚期HCC患者。记录每例患者的疾病无进展生存期（PFS），并对所有可能影响患者PFS的因素进行分析。使用SPSS 17.0 统计软件进行统计分析，以P＜0.05表示差异有统计学意义。
结果?本研究患者的中位PFS（mPFS）是14个月；BCLC B期患者mPFS为18个月，而BCLC C期患者为8个月；治疗前AFP＜400 ng/mL患者mPFS为16个月，而治疗前AFP≥400 ng/mL患者为11个月；高血压患者mPFS为18个月，无高血压患者为10个月；蛋白尿患者mPFS为19个月，而无蛋白尿患者为12个月；伴手足综合征患者mPFS为16个月，而无手足综合征患者为9个月，以上差异均有统计学意义（P＜0.05）。结论?BCLC分期、治疗前AFP水平以及高血压、蛋白尿、手足综合征的发生情况是TACE联合阿帕替尼治疗中晚期HCC患者PFS的影响因素，且BCLC分期和高血压的发生情况是影响患者PFS的独立预后因素。

参考文献/References:

[1] 陆?阳， 姜永能， 万?程， 等. 阿帕替尼联合TACE治疗中晚期肝细胞癌的疗效研究[J]. 介入放射学杂志， 2019， 28：162-165.
[2] Shan F, Miao R, Xue K, et al. Controlling angiogenesis in gastric cancer: A systematic review of anti-angiogenic trials[J]. Cancer Lett, 2016, 380: 598-607.
[3] 杨泽冉， 苏天昊， 尉建安， 等. 肝动脉化疗栓塞术联合阿帕替尼治疗中晚期原发性肝癌疗效评价[J]. 中国肿瘤临床， 2017， 44：880-885.
[4] 时佳琪， 刘?超， 张艳桥， 等. 甲磺酸阿帕替尼治疗恶性肿瘤的临床不良反应分析[J]. 中国肿瘤临床， 2018， 45：191-195.
[5] Kamiyama T, Yokoo H, Kakisaka T, et al. Multiplication of alpha-fetoprotein and protein induced by vitamin K absencmH is a powerful predictor of prognosis and recurrence in hepatocellular carcinoma patients after a hepatectomy[J]. Hepatol Res, 2015, 45: e21-e31.
[6] Yamada R, Hiramatsu N, Oze T, et al. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection[J]. J Gastroenterol, 2015, 50: 785-794.
[7] 甘?雨， 田娜娜， 陈华辉， 等. 原发性肝癌患者AFP浓度与临床特点及预后的相关性[J]. 中华肿瘤防治杂志， 2016， 23：958-962.
[8] Aldrighetti L, Pulitano C, Catena M, et al. Liver resection with portal vein thrombectomy for hepatocellular carcinoma with vascular invasion[J]. Ann Surg Oncol, 2009, 16: 1254.
[9] Lankhorst S, Kappers MH, van Esch JH, et al. Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress[J]. Antioxid Redox Signal, 2014, 20: 135-145.
[10] Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors[J]. Nat Med, 2003, 9: 669-676.
[11] Rosenbaum SE, Wu S, Newman MA, et al. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib[J]. Support Care Cancer, 2008, 16: 557-566.
[12] Narasimhan P, Narasimhan S, Hitti IF, et al. Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature[J]. Cutis, 2004, 73: 101-106.

相似文献/References:

[1]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良ＲＥＣＩＳＴ标准更可靠[J].介入放射学杂志,2012,(03):177.
　. Ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ ｃｒｉｔｅｒｉｏｎ ｏｆ ｉｎｏｐｅｒａｂｌｅ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ｍｏｄｉｆｉｅｄ ＲＥＣＩＳＴ ａｓ ａ ｍｏｒｅ ｒｅｌｉａｂｌｅ ｓｔａｎｄａｒｄ[J].journal interventional radiology,2012,(03):177.
[2]陆骊工,胡宝山,李勇,等.中晚期原发性肝癌合并症的介入治疗研究[J].介入放射学杂志,2008,(07):514.
　LU Ligong,HU Baoshan,LI Yong,et al.Study of interventional therapy for complications in advanced primary hepatocellular carcinoma[J].journal interventional radiology,2008,(03):514.
[3]李晓光,金征宇,潘杰,等.肝动脉化疗或栓塞治疗胰腺神经内分泌肿瘤肝转移的疗效分析[J].介入放射学杂志,2010,(06):442.
　LI Xiaoguang,JIN Zhengyu,PAN Jie,et al.Hepatic transarterial chemoperfusion and chemoembolization for the treatment of liver metastases from pancreatic neuroendocrine tumors：a therapeutic analysis[J].journal interventional radiology,2010,(03):442.
[4]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
　.Ｔｈｅ ｔｒａｎｓｆｏｒｍａｔｉｏｎ ｐａｔｔｅｒｎ ｏｆ ｓｅｒｕｍ аｆｅｔｏｐｒｏｔｅｉｎ ａｆｔｅｒ ｔｒａｎｓｃａｔｈｅｔｅｒ ａｒｔｅｒｉａｌ ｃｈｅｍｏｅｍｂｏｌｉｚａｔｉｏｎ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａ： ｉｔｓ ｃｌｉｎｉｃａｌ ｓｉｇｎｉｆｉｃａｎｃｅ [J].journal interventional radiology,2012,(03):333.
[5]杨学东,张志良,马戈,等.肝动脉化疗栓塞与三维立体定向放疗配合治疗原发性肝癌[J].介入放射学杂志,2009,(03):193.
　YANG Xuedong,ZHANG Zhiliang,MA Ge,et al.Hepatic arterial chemoembolization combined with３D conformal radiotherapy for primary hepatic carcinoma[J].journal interventional radiology,2009,(03):193.
[6]郑加生,李建军,崔雄伟,等.肝动脉化疗栓塞联合CT引导下射频消融术治疗肝癌的疗效分析[J].介入放射学杂志,2009,(05):324.
　ZHENG Jia-sheng,LI Jian-jun,CUI Xiong-wei,et al.Therapeutic combination of hepatic arterial chemoembolization with CT鄄guided radiofrequency ablation for hepatocellular carcinoma：an analysis of curative effect[J].journal interventional radiology,2009,(03):324.
[7]刘德鑫,李华东,李新丰,等.肝动脉栓塞化疗联合射频及无水乙醇注射治疗中晚期肝癌的评价[J].介入放射学杂志,2009,(05):389.
　LIU De-xin,LI Hua-dong,LI Xin-feng,et al.Evaluation of TACE combined with RFA and PEI in treating advanced hepatic carcinoma[J].journal interventional radiology,2009,(03):389.
[8]周怡婷,曹建民,许健,等.氩氦刀联合栓塞化疗治疗中晚期肝癌的临床研究[J].介入放射学杂志,2009,(10):733.
　ZHOU Yiting,CAO Jianming,XU Jian,et al.Cryotherapy combined with chemoembolization for the treatment of advanced hepatic carcinoma ：a clinical study[J].journal interventional radiology,2009,(03):733.
[9]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
　,,et al.Ｔｈｅ ｆａｃｔｏｒｓ ｒｅｌａｔｅｄ ｔｏ ｔｈｅ ｆｏｒｍａｔｉｏｎ ｏｆ ａｒｔｅｒｉｏｐｏｒｔａｌ ｓｈｕｎｔｉｎｇ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ [J].journal interventional radiology,2012,(03):206.
[10]纪昌学,陈宪,涂蓉,等.经肝动脉化疗栓塞对高危因素肝癌的疗效观察[J].介入放射学杂志,2007,(06):378.
　JI Chang-xue,CHEN Xian,TU Rong,et al.Therapeutic efficacy of transcatheter arterial chemoembolization for liver cancer with high-risk factors[J].journal interventional radiology,2007,(03):378.

备注/Memo

备注/Memo:
（收稿日期：2019-05-19）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2020-04-16